SCHEMBL4668971

SCHEMBL4668971

CC(Br)Cc1cccc(Cl)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 2/20 0.69
TSHR P16473 1/20 0.49
RECQL P46063 1/20 0.49
TAAR1 Q96RJ0 3/20 0.47
CHRM2 P08172 1/20 0.46
SIGMAR1 Q99720 1/20 0.46
CYP3A4 P08684 2/20 0.46
IDO1 P14902 2/20 0.46
AGXT P21549 2/20 0.46
AOC3 Q16853 1/20 0.44
HTR3E A5X5Y0 2/20 0.43
HTR3B O95264 2/20 0.43
HTR3A P46098 2/20 0.43
HTR3D Q70Z44 2/20 0.43
HTR3C Q8WXA8 2/20 0.43
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL777207 0.83 PNMT (0.74) PNMTTSHRRECQLTAAR1CHRM2
SCHEMBL14478283 0.82 PNMT (1.00) PNMTTSHRRECQLTAAR1SIGMAR1
SCHEMBL30363681 0.82 PNMT (1.00) PNMTTSHRRECQLTAAR1SIGMAR1
Ammonia Solution, Strong SCHEMBL27650008 0.82 PNMT (0.71) PNMTTSHRRECQLTAAR1CHRM2
SCHEMBL266685 0.82 PNMT (1.00) PNMTTSHRRECQLTAAR1SIGMAR1
SCHEMBL20353178 0.80 PNMT (0.69) PNMTTSHRRECQLTAAR1CHRM2
SCHEMBL7489958 0.80 PNMT (0.69) PNMTTSHRRECQLTAAR1CHRM2
SCHEMBL21076141 0.80 PNMT (0.69) PNMTTSHRRECQLTAAR1CHRM2
SCHEMBL2427261 0.80 PNMT (0.69) PNMTTSHRRECQLTAAR1CHRM2
SCHEMBL16379378 0.80 PNMT (0.69) PNMTTSHRRECQLTAAR1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1930308-A1 Pharmaceutical agents for the treatment of cerebral amyloidosis NYMOX CORPORATION (CA) 2008-06-11 EP disclosed
EP-0983222-B1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORP (CA) 2007-11-28 EP disclosed
US-6518314-B1 For treating cerebral amyloidosis; compounds that impede the transformation of dense microspheres (DMS) into amyloid NYMOX CORPORATION (CA) 2003-02-11 US disclosed
US-6130221-A ALZHEIMERS NYMOX CORPORATION (CA) 2000-10-10 US disclosed
EP-0983222-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 2000-03-08 EP disclosed
WO-1998052898-A9 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORP (CA) 1999-04-01 WO disclosed
WO-1998052898-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 1998-11-26 WO disclosed